Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: Basal state and effect of successful dilation

American Heart Journal

Volumn 137, Issue 2, 1999, Pages 274-283

  Lehmann, Kenneth G ^a   Gonzales, Emma ^b   Tri, Bui D ^b   Vaziri, Nosratola D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12; D DIMER; FIBRINOGEN; FIBRINOLYTIC FACTOR; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA PROTEIN; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGINA PECTORIS; ARTERIAL BLOOD; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032938607     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v137.91540     Document Type: Article

References (50)

1. 1. Block PC, Baughman KL, Pasternak RC, Fallon JT. Transluminal angioplasty: correlation of morphologic and angiographic findings in an experimental model. Circulation 1980;61:778-85.
2. 2. Faxon DP, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis 1982;2:125-33.
3. 3. Block PC, Myler RK, Stertzer S, Fallon JT. Morphology after transluminal angioplasty in human beings. N Engl J Med 1981; 305:382-5.
4. 4. Kochi K, Takebayashi S, Block PC, Hiroki T, Nobuyoshi M. Arterial changes after percutaneous transluminal coronary angioplasly: results at autopsy. J Am Coll Cardiol 1987;10:592-9.
5. 5. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam J, Holmes DR, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988;78:654-60.
6. 6. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
7. 7. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60:20B-8B.
8. 8. de Feyter PJ, van den Brand M, Jaarman G, van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 1991;83:927-36.
9. 9. Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996;131:1-6.
10. 10. Berk BC, Taubman MB, Griendling KK, Cragoe EJ Jr, Fenton JW, Brock TA. Thrombin-stimulated events in cultured vascular smooth muscle cells. Biochem J 1991;274:799-805.
11. 11. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardial 1991;17:77B-88B.
12. 12. Greuntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis: percutaneous transluminal angioplasty. N Engl J Med 1979;301:61-8.
13. 13. Swanson KT, Vlietstra RE, Holmes DR, Smith HC, Reeder GS, Bresnaham JF, et al. Efficacy of adjunctive dextran during percutaneous transluminal coronary angioplasty. Ann Intern Med 1985;102:447-8.
14. 14. Thornton MA, Greuntzig AR, Hollman J, King SB, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984; 69:721-7.
15. 15. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
16. 16. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9.
17. 17 Laskey MAL, Deutsch E, Hirshfeld JW Jr, Kussmaul WG, Barnathan E, Loskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-82.
18. 18. Ellis SG, Roubin GS,Wilentz J, Douglas JS Jr, King SB III. Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117:777-82.
19. 19. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991;17:96B-100B.
20. 20. Branson HE, Slater LM, Anderson MG, Pirkle H. Prothrombin time after heparin removal. Application to monitoring simultaneous anticoagulation with heparin and coumarins. Am J Clin Path 1979;71:665-7.
21. 21. Meade TJ, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
22. 22. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989;77:209-13.
23. 23. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
24. 24. Swahn E, Von Schenck H, Wallentil L. Plasma fibrinogen in unstable coronary artery disease. Scond J Clin Lab Invest 1989;49:49-54.
25. 25. Schmitz-Huebner U, Thompson SG, Balleisen L, Fechtrup C, Grosse-Heitmeier W, Kirchhof B, et al. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J 1988;59:287-91.
26. 26. Gordon EM, Hellerstein HK, Ratnoff OD, Arafah BM, Yamashita TS. Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction. J Lab Clin Med 1987;109:409-13.
27. 27. Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989;80:1617-26.
28. 28. Wilensky RL, Zeller JA, Wish M, Tulchinsky M. Urinary fibrinopeptide A levels in ischemic heart disease. J Am Coll Cardiol 1989; 14:597-603.
29. 29. Theroux P, Latour J-G, Leger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987;75:156-62.
30. 30. Rapold H, Haeberli A, Kuemmerli H, Weiss M, Bauer HR, Straub WP. Fibrin formation and platelet activation in patients with myocardial infarction and normal coronary arteries. Eur Heart J 1989;10:323-33.
31. 31. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-91.
32. 32. Gonzales R, Vicente V, Alegre A, Pabon P, Alberca I. Protein C and antithrombin III in acute myocardial infarction. Thromb Res 1986; 43:681-5.
33. 33. Innerfield I, Goldfischer JD, Reicher-Reiss J, Greenberg J. Serum antithrombin in coronary artery disease. Am J Clin Pathol 1976; 65:64-8.
34. 34. Iso H, Folsom AR, Wu KK, Finch A, Sato S, Munger RG, et al. Hemostatic variables in Japanese and Caucasian men. J Epidem 1990;132:41-6.
35. 35. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
36. 36. Zalewski A, Shi Y, Nardone D, Brevette B, Weinstock P, Fischman D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest: clinical, biochemical, and angiographic correlates. Circulation 1991;83:1685-91.
37. 37. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987;317:1361-5.
38. 38. Soria C, Soria J, Mirshahi MC, Mirshahi M, Dunnica S, Boucheix C, et al. Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination. Thromb Res 1987; 45:383-92.
39. 39. Rogers S, Sweetnam PM, Perry MJ, Gaffney J. Plasma levels of fibrin fragments in men with myocardial infarction. Thromb Res 1986; 43:389-93.
40. 40. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinotytic and kaltikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-7.
41. 41. Alexopoulos D, Ambrose J, Stump D, Borrico S, Gorlin R, Deshmukh P, et al. Thrombosis-related markers in unstable angina pectoris. J Am Coll Cardiol 1991;17:866-71.
42. 2-antiplasmin. J Am Coll Cardiol 1990;15:1212-20.
43. 2-antiplasmin enhances in vivo thrombolysis. Circulation 1990;82: 164-8.
44. 44. Brenner B, Francis CW, Totterman S, Kessler C, Rao AK, Rubin R, et al. Quantitarion of venous clot lysis of the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation 1990;81:1818-25.
45. 45. Francis CW, Connaghan G, Marder V. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986;74:1027-36.
46. 46. Francis CW, Connaghan G, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987;75:1170-7.
47. 47. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88:2728-34.
48. 48. Ikeda H, Nakayama H, Oda T, Kuwano K, Yamaga A, Ueno T, et al. Neutrophil activation after percutaneous transluminal coronary angioplasty. Am Heart J 1994;128:1091-8.
49. 49. Ring ME, Vecchione JJ, Fiore LD, Ruocco Jr NA, Jacobs AK, Deykin D, et al. Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Cardiol 1991;67:1330-4.
50. 50. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, et al. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991;83:1692-7